<?xml version='1.0' encoding='utf-8'?>
<document id="27719741"><sentence text="Evaluation of the safety, pharmacokinetics, pharmacodynamics, and drug-drug interaction potential of a selective Lp-PLA2 inhibitor (GSK2647544) in healthy volunteers ." /><sentence text="To evaluate in healthy volunteers the safety, pharmacokinetics (PK), pharmacodynamics (PD), and drug-drug interaction (DDI) potential of GSK2647544, (a selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor)" /><sentence text="" /><sentence text="Study 1 was a single-blind, randomized, placebo-controlled, crossover study with healthy male volunteers randomized to receive single escalating oral doses (0" /><sentence text="5 - 750 mg) of GSK2647544" /><sentence text=" Study 2 was a single-blind, randomized, placebo-controlled study with healthy volunteers randomized to receive repeat doses (80 mg) of GSK2647544" /><sentence text=" The drug-drug interaction of GSK2647544 with simvastatin was also evaluated in study 2"><entity charOffset="46-57" id="DDI-PubMed.27719741.s7.e0" text="simvastatin" /></sentence><sentence text="" /><sentence text="Across both studies GSK2647544 doses were generally well tolerated with no GSK2647544-related clinically significant findings" /><sentence text=" GSK2647544 was readily absorbed and its plasma concentration declined bi-exponentially with a terminal half-life ranging from 8 to 16 hours" /><sentence text=" Plasma exposure of GSK2647544 increased approximately dose-proportionally" /><sentence text=" There was GSK2647544 dose-dependent inhibition of plasma Lp-PLA2 activity, with a trough inhibition (12 hours after dose) of 85" /><sentence text="6% after 7-day twice daily dosing" /><sentence text=" The administration of simvastatin concomitantly with GSK2647544 increased the overall exposure (area under the plasma concentration-time curve and maximum plasma concentration) of simvastatin and simvastatin acid by 3"><entity charOffset="23-34" id="DDI-PubMed.27719741.s14.e0" text="simvastatin" /><entity charOffset="181-192" id="DDI-PubMed.27719741.s14.e1" text="simvastatin" /><entity charOffset="197-213" id="DDI-PubMed.27719741.s14.e2" text="simvastatin acid" /><pair ddi="false" e1="DDI-PubMed.27719741.s14.e0" e2="DDI-PubMed.27719741.s14.e0" /><pair ddi="false" e1="DDI-PubMed.27719741.s14.e0" e2="DDI-PubMed.27719741.s14.e1" /><pair ddi="false" e1="DDI-PubMed.27719741.s14.e0" e2="DDI-PubMed.27719741.s14.e2" /><pair ddi="false" e1="DDI-PubMed.27719741.s14.e1" e2="DDI-PubMed.27719741.s14.e1" /><pair ddi="false" e1="DDI-PubMed.27719741.s14.e1" e2="DDI-PubMed.27719741.s14.e2" /></sentence><sentence text="6- to 4" /><sentence text="3-fold and 1" /><sentence text="5- to 3" /><sentence text="1-fold, respectively" /><sentence text="" /><sentence text="GSK2647544 was generally well tolerated and had a reasonable PK-PD profile" /><sentence text=" The clinically significant drug-drug interaction led to an early termination of study 2" /><sentence text=" " /><sentence text="" /></document>